The Ohio State University Corporate Engagement Office

Back to All Technologies

Novel Use of Fostamatinib as a Therapeutic for Liver Cancer, both as First-Line Therapy and Following Acquired Resistance to Sorafenib

Healthcare Portfolios
Life Sciences
Drug Screening & Discovery
Oncology
Small Molecules
Therapeutics
College
College of Medicine (COM)
Researchers
Motiwala, Tasneem
Regan, Kelly
Reyes, Ryan
Licensing Manager
Flammang, Ann Marie
614-292-9839
flammang.2@osu.edu

TS-032418 — A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) kills nearly all patients within a year of diagnosis, and results in between 250,000 and one million deaths globally per year. In the US, incidences of HCC have nearly tripled in the past 30 years and currently remain one of the fastest growing causes of cancer-relat…

The Need

Hepatocellular carcinoma (HCC) kills nearly all patients within a year of diagnosis, and results in between 250,000 and one million deaths globally per year. In the US, incidences of HCC have nearly tripled in the past 30 years and currently remain one of the fastest growing causes of cancer-related deaths (Goossens, Sun et al. 2015). Long-term patient prognosis is extremely poor and treatment options are limited. Currently, sorafenib is the only FDA-approved systemic therapy for advanced HCC in the United States, but patient development of sorafenib resistance is commonly observed (Yegin, Oymaci et al. 2016), underscoring the need for new and effective therapy against this deadly disease. Due to the time and cost associated with new drug discovery, repurposing currently approved drugs for use against HCC could be a more rapid and cost-effective approach to deliver treatment options for patients currently battling the disease.

The Technology

Inventors at the Ohio State University led by Dr. Tasneem Motiwala have developed a therapy based on the use of fostamatinib, either alone or in combination with sorafenib. Drug repurposing analysis identified fostamatinib as a candidate that could reverse the gene expression signature of sorafenib resistant liver cancer cell line. Fostamatinib is also effective against sorafenib-sensitive liver cancer cell lines.

Although fostamatinib has not previously been identified as an effective treatment for HCC, it has been included in numerous clinical trials to determine safety and efficacy for other uses, indicating promise for future inclusion as a combinatorial therapy in human patients with HCC.

Commercial Applications

  • Pharmaceuticals
  • Oncology treatments
  • Combination therapies

Benefits/ Advantages

  • Reduction in time and cost of traditional drug discovery
  • Expedited clinical trials
  • Reverses gene expression signature of primary liver cancer

Intellectual Property

PCT has been filed